Literature DB >> 17217374

Is arterial stiffening in Alström syndrome linked to the development of cardiomyopathy?

J C Smith1, B McDonnell, C Retallick, C McEniery, C Carey, J S Davies, T Barrett, J R Cockcroft, R Paisey.   

Abstract

BACKGROUND: Alström syndrome (AS) is a rare autosomal recessive condition characterized by retinal degeneration, childhood obesity, and severe insulin resistance. Dilated cardiomyopathy of unknown aetiology is a well-recognized and potentially lethal complication. The aim of this study was to investigate the relationship between vascular function, hyperinsulinaemia and cardiac performance in AS.
MATERIALS AND METHODS: Fifteen subjects with AS (mean age 21 years, range 10-35) were studied and compared with age-, sex-, and blood pressure-matched healthy controls. Large artery stiffness and wave reflections were assessed in both groups by measuring aortic and brachial pulse wave velocity (PWV) (carotid-femoral and carotid-radial) and augmentation index (AIX) (Sphygmocor). In AS subjects, left ventricular function was assessed by echocardiography and metabolic parameters including fasting insulin, glucose, lipids and brain natriuretic peptide were also measured.
RESULTS: Comparing AS subjects vs. controls (mean +/- SD), AIX was elevated in AS subjects (18 +/- 9% vs. 3 +/- 11%, P < 0.0001). No significant changes in brachial PWV (8.1 +/- 1.3 m s(-1) vs. 7.3 +/- 1.1 m s(-1), P = 0.14) or aortic PWV (6.5 +/- 1.1 m s(-1) vs. 6.0 +/- 1.0 m s(-1), P = 0.26) were observed. AS subjects were hyperinsulinaemic and had disturbances in lipid profiles relative to controls. No correlations were observed between vascular, metabolic and echocardiographic parameters.
CONCLUSIONS: In AS there are alterations in the shape of the central arterial pressure waveform associated with augmented aortic systolic pressure and indicative of increased wave reflection. Unfavourable central arterial haemodynamics in AS may contribute to the development of cardiomyopathy but other aetiological factors are probably involved.

Entities:  

Mesh:

Year:  2007        PMID: 17217374     DOI: 10.1111/j.1365-2362.2007.01759.x

Source DB:  PubMed          Journal:  Eur J Clin Invest        ISSN: 0014-2972            Impact factor:   4.686


  6 in total

1.  Alström Syndrome: Mutation Spectrum of ALMS1.

Authors:  Jan D Marshall; Jean Muller; Gayle B Collin; Gabriella Milan; Stephen F Kingsmore; Darrell Dinwiddie; Emily G Farrow; Neil A Miller; Francesca Favaretto; Pietro Maffei; Hélène Dollfus; Roberto Vettor; Jürgen K Naggert
Journal:  Hum Mutat       Date:  2015-05-18       Impact factor: 4.878

Review 2.  Alström syndrome: insights into the pathogenesis of metabolic disorders.

Authors:  Dorothée Girard; Nikolai Petrovsky
Journal:  Nat Rev Endocrinol       Date:  2010-12-07       Impact factor: 43.330

3.  Coronary artery disease in Alström syndrome.

Authors:  Kumar Jatti; Richard Paisey; Ranjit More
Journal:  Eur J Hum Genet       Date:  2011-09-07       Impact factor: 4.246

4.  Alström syndrome: genetics and clinical overview.

Authors:  Jan D Marshall; Pietro Maffei; Gayle B Collin; Jürgen K Naggert
Journal:  Curr Genomics       Date:  2011-05       Impact factor: 2.236

5.  Duration of Diabetes Predicts Aortic Pulse Wave Velocity and Vascular Events in Alström Syndrome.

Authors:  Richard B Paisey; Jamie Smith; Catherine Carey; Timothy Barrett; Fiona Campbell; Pietro Maffei; Jan D Marshall; Christopher Paisey; Richard P Steeds; Nicola C Edwards; Susan Bunce; Tarekegn Geberhiwot
Journal:  J Clin Endocrinol Metab       Date:  2015-06-11       Impact factor: 5.958

Review 6.  Mutation identification and prediction for severe cardiomyopathy in Alström syndrome, and review of the literature for cardiomyopathy.

Authors:  Savas Dedeoglu; Elif Dede; Funda Oztunc; Asuman Gedikbasi; Gozde Yesil; Reyhan Dedeoglu
Journal:  Orphanet J Rare Dis       Date:  2022-09-15       Impact factor: 4.303

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.